Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies
Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining cancer cell-directed and immune cell-targeting compounds, further strengthening the company’s pipeline.
Cancer immunotherapies have brought dramatic breakthroughs, but only for a minority of cancer patients. 3T‘s platform aims to address this challenge by identifying novel shared T-cell receptor (TCR) targets of productive immune responses and comprehensively screening TCRs and TCR mimetics for specificity and off-target cross-reactivities. The platform identifies the most prevalent and immunogenic targets in solid tumors by uniquely combining high-diversity target libraries with active machine learning. This may lead to tumor-specific, safer therapies that can be delivered at higher doses.
“At Boehringer Ingelheim, we are committed to transforming patients’ lives. Through our new partnership with 3T Biosciences, we aim at accelerating and expanding our pipeline of first-in-class T-cell based therapies for patients affected by cancer,” said Lamine Mbow, Ph.D., Global Head of Cancer Immunology + Immune Modulation, Boehringer Ingelheim.
“On behalf of the entire team at 3T Biosciences, we are extremely pleased to partner with Boehringer Ingelheim, a company advancing transformative cancer treatments,” said Stefan J. Scherer, M.D., Ph.D., president and CEO of 3T Biosciences. “3T’s 3T-TRACE discovery platform has the potential to transform the treatment of cancers and beyond. By using data from patients for patients we aim to discover the best immunogenic targets for multiple tumor indications and across patient populations.”
Under the agreement, Boehringer Ingelheim will provide patient-derived TCR data to fuel 3T’s target discovery efforts to identify antigens using its 3T TRACE discovery platform. 3T will receive an upfront payment and research and development support, and is eligible for discovery, preclinical, clinical, regulatory, and commercial milestones totaling $268 million in addition to royalties on future Boehringer Ingelheim product sales. Boehringer Ingelheim is eligible to receive royalties on future product sales by 3T Biosciences arising from the agreement.
For the full press release and link to “Notes to Editors” please click here:
Press Release
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005420/en/
Contact information
Media contacts:
B
oehringer Ingelheim
Dr. Reinhard Malin
Boehringer Ingelheim Corporate Center GmbH
Innovation Unit/Bio Comms, Corp. Affairs
Media + PR
press@boehringer-ingelheim.com
Linda Ruckel
Boehringer Ingelheim Corporate Center GmbH
Innovation Unit/Bio Comms, Corp. Affairs
Media + PR
P: 203-791-6672
press@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gallagher Re Joins ABIR and EY as 2023 Bermuda Risk Summit Headline Sponsors3.2.2023 18:17:00 EET | Press release
The Bermuda Business Development Agency (BDA) is pleased to announce that Gallagher Re has joined the Association of Bermuda Insurers and Reinsurers (ABIR) and EY as headline sponsors of the second annual Bermuda Risk Summit. Adam Schwebach, Executive Vice President, Gallagher Re, said, “Gallagher Re is proud to support the second Bermuda Risk Summit, an annual event that showcases the breadth and versatility of Bermuda’s globally significant risk market. This event serves as a timely opportunity to connect with industry leaders ahead of midyear renewals and we applaud the BDA for their efforts in making the Bermuda Risk Summit a success.” David Hart, BDA CEO, said, “We are just so excited to welcome Gallagher Re as our third and final headline sponsor, along with ABIR and EY. The theme of the 2023 Bermuda Risk Summit, being held from March 6-8, 2023, at the Hamilton Princess & Beach Club is ‘Innovation, Sustainability and Collaboration. We anticipate an even stronger attendance level
Workato Named a Leader in the 2023 Gartner® Magic Quadrant™ for iPaaS3.2.2023 18:15:00 EET | Press release
Workato, the leading enterprise automation and integration platform, announced today that it has again been recognised as a Leader in the 2023 Gartner® Magic Quadrant™ for Integration Platform as a Service. Workato has been named a Leader all five years it has participated in the Gartner® Magic Quadrant™ for iPaaS. The report evaluated 16 total software vendors and placed Workato in the Leaders quadrant for its ability to execute, and completeness of vision. For us, Workato’s position within the Leaders quadrant signals one of the best positionings of a modern iPaaS to date. The Workato platform enables enterprises to automate their business processes across the entire organization by integrating their applications, data, and experiences. Designed with best-in-class security and governance, scalability, performance, and availability, Workato’s low-code, no-code platform makes it easy for IT and business teams to integrate their applications and automate their processes, drawing from th
Suzano Eucafluff to Attend INDEX and CIDPEX in 20233.2.2023 16:58:00 EET | Press release
Suzano, the world’s largest hardwood pulp producer, will showcase its highly sustainable and innovative eucalyptus-based fluff pulp, Eucafluff®, at this year’s INDEX and CIDEPX conferences in Geneva and Nanjing, for the second consecutive year. These two conferences gather the pulp industry’s leading participants in nonwoven materials comprising decision-makers, managers, and technical personnel. Suzano will be presenting significant advancements in Eucafluff’s product application and performance. INDEX is one of the world’s largest nonwovens exhibitions exploring the industry’s latest trends and innovations. The event takes place on 18-21 April 2023 in Geneva, Switzerland. CIDPEX – The China International Disposable Paper Expo - is another important event for Suzano which stages the latest advancements across the tissue paper and disposable hygiene products sector. The event takes place on 12-16 May 2023 in Nanjing, China. Eucafluff® is made from sustainably managed eucalyptus farms i
Uptime Institute Completes Acquisition of CNet Training, the International Award-Winning Technical Education Company3.2.2023 16:01:00 EET | Press release
Uptime Institute, the Global Digital Infrastructure Authority, a Dominus Capital, L.P. portfolio company, announced today that it has completed its acquisition of Academia Group Limited and all of its global subsidiaries including CNet Training, Ltd. CNet Training, located in Bury Saint Edmunds, Suffolk, England, is an International award-winning technical education company. CNet Training has been designing and delivering professional network and data center infrastructure training programs since 1996 and has trained over 83,000 data center professionals across 45 countries. “The data center industry is one of the fastest growing markets in the world. The continued, extraordinary industry expansion requires a growing and diverse workforce, however concerns over the industry’s ability to attract, educate, and retain skilled technical staff persist. This acquisition will help our respective customers thrive in a rapidly changing ecosystem, by giving them access to a range of world class
Dexlevo’s GOURI Symposium and Brand Event at IMCAS 20233.2.2023 11:15:00 EET | Press release
Dexlevo, a company specializing in aesthetic medical devices, successfully held a symposium dedicated to its exclusive product, ‘GOURI’, at the IMCAS World Congress 2023 in Paris. IMCAS (International Master Course on Aging Science), held from Jan 26th to Jan 28th in Paris, France, is one of the world's three major aesthetics anti-aging societies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230202005935/en/ GOURI Booth at IMCAS Paris 2023 (Photo: Business Wire) Over 200 doctors and companies who visited Dexlevo's booth showed great interest in GOURI – a unique injectable that provides a fundamental solution to anti-aging. GOURI symposium titled “Universal Anti-Aging Treatment” was conducted by an Australian dermatologist Dr. Paul Han, who apart from giving a lecture also demonstrated a new GOURI treatment protocol which lately has gained increasing popularity among doctors who use GOURI. Dr. Paul commented, “While keeping
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom